Autosomal-dominant missense mutations in LRRK2 (leucinerich repeat kinase 2) are a common genetic cause of PD (Parkinson's disease). LRRK2 is a multidomain protein with kinase and GTPase activities. Dominant mutations are found in the domains that have these two enzyme activities, including the common G2019S mutation that increases kinase activity 2-3-fold. However, there is also a genetic variant in some populations, G2385R, that lies in a C-terminal WD40 domain of LRRK2 and acts as a risk factor for PD. In the present study we show that the G2385R mutation causes a partial loss of the kinase function of LRRK2 and deletion of the C-terminus completely abolishes kinase activity. This effect is strong enough to overcome the kinase-activating effects of the G2019S mutation in the kinase domain. Hsp90 (heat-shock protein of 90 kDa) has an increased affinity for the G2385R variant compared with WT (wild-type) LRRK2, and inhibition of the chaperone binding combined with proteasome inhibition leads to association of mutant LRRK2 with high molecular mass native fractions that probably represent proteasome degradation pathways. The loss-of-function of G2385R correlates with several cellular phenotypes that have been proposed to be kinase-dependent. These results suggest that the C-terminus of LRRK2 plays an important role in maintaining enzymatic function of the protein and that G2385R may be associated with PD in a way that is different from kinase-activating mutations. These results may be important in understanding the differing mechanism(s) by which mutations in LRRK2 act and may also have implications for therapeutic strategies for PD.
INTRODUCTION
PD (Parkinson's disease) is a neurodegenerative disorder with varied symptoms, including tremor, rigidity and postural instability [1] . The most common monogenic cause of PD are dominant missense mutations in the LRRK2 [LRR (leucine-rich repeat) kinase 2] gene [2] [3] [4] . Clinically, LRRK2-associated PD is indistinguishable from idiopathic cases [5] .
LRRK2 is a large (286 kDa) complex protein that possesses two enzymatic domains, a ROC (Ras of complex proteins) domain that binds GTP and a kinase domain. The COR (C-terminus of ROC) domain is found between ROC and kinase domains and may contribute to the formation of LRRK2 dimers and regulation of GTP binding [6] . Other domains, including LRR and WD40 domains are proposed to participate in protein-protein interactions of LRRK2. One mutation, G2019S in the kinase domain, increases kinase activity, whereas mutations in the ROC and COR domain decrease GTPase activity [7] [8] [9] [10] . It is thought that these two observations are linked in that there is evidence of communication between the GTPase and kinase activities, although the precise molecular basis is poorly understood [11] .
In contrast, the function of the WD40 domain of LRRK2 remains relatively unknown. Deletion of the WD40 domain and the extreme C-terminus decreases kinase activity and limits neurotoxicity, possibly due to diminished dimer formation [12] . However, deletion of only the last 7 amino acids at the extreme C-terminus of LRRK2 also completely abolishes kinase activity [13] . Therefore, it is unclear whether the effects of deletions at the C-terminus on toxicity are due to the WD40 domain itself or are related to kinase activity.
Several amino acid variants in the WD40 domain have been found, and one, G2385R, shows a genetic association with PD [14, 15] . The effects of G2385R on LRRK2 kinase activity are controversial. Some reports have shown that G2385R LRRK2 has a decreased kinase activity [13] , whereas others did not find any significant difference compared with WT (wild-type) protein [10, 16] . The G2385R substitution decreases 14-3-3 binding mediated by phosphorylation of the Ser 910 /Ser 935 residues, which are both proposed to be cellular correlates of kinase activity of LRRK2 [16] .
In the present study we assessed how the G2385R variant affects the functional properties of the LRRK2 protein. We found that G2385R decreased kinase activity, phosphorylation of LRRK2 in vivo and the ability to bind 14-3-3 proteins by approximately half of the WT protein. At the same time, this mutation increased binding to Hsp90 (heat-shock protein of 90 kDa), which plays a role in maintaining LRRK2 stability. The effect on in vitro kinase activity was seen whether G2385R was present on a WT background or whether the constructs also contained the activating G2019S mutation. Additionally, G2385R LRRK2 had a different profile on size-exclusion chromatography compared with WT protein.
We speculate that G2385R destabilizes LRRK2 structure, partially misfolds the protein, and thus impairs LRRK2 function.
MATERIALS AND METHODS

Constructs
The 2×Myc-LRRK2 constructs were cloned into pCMV plasmid as described previously [7] . The 3×FLAG-tagged construct of LRRK2 in pCHMWS plasmid was a gift from Dr J.-M. Taymans (De Katholieke Universiteit van Leuven, Belgium). Mutagenesis was performed using QuikChange II XL SiteDirected Mutagenesis Kit (Stratagene). All plasmids were analysed with EcoRI and EcoRV restriction enzymes (Fermentas) and fully sequenced.
In vitro kinase assays
HEK (human embryonic kidney)-293FT cells were transiently transfected with 3×FLAG-LRRK2 plasmid using polyethylenimine (Sigma), harvested 48 h after transfection and lysed with buffer containing 20 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM sodium EDTA, 1 mM EGTA, 1 % (v/v) Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM 2-glycerophosphate, 1 mM Na 3 VO 4 and 1 μg/ml of leupeptin (Cell Signaling Technology) supplemented with protease inhibitor cocktail (Roche). Lysates were pre-cleared with EZview Red Protein G affinity gel (Sigma) for 30 min and immunoprecipitated using EZview Red anti-FLAG M2 affinity gel (Sigma) for 2 h. Complexes were then washed three times with wash buffer [25 mM Tris/HCl, pH 7.5, 400 mM NaCl and 1 % (v/v) Triton X-100] and once with kinase buffer (25 mM Tris/HCl, pH 7.5, 5 mM 2-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na 3 VO 4 and 10 mM MgCl 2 ). LRRK2 was eluted with 200 μg/ml of 3×FLAG-peptide (Sigma) in kinase buffer with 0.02 % Triton X-100 for 1 h. To achieve reproducible data in the kinase assays, LRRK2 protein concentrations were estimated before the experiments by running aliquots and BSA standards on SDS/PAGE (4-20 % Criterion TGX pre-cast gels; Bio-Rad Laboratories) with subsequent staining with GelCode Blue Stain Reagent (Thermo Scientific). In some experiments, we treated cells with 1 μM geldanamycin for 2 h at 37
• C. In preliminary experiments, this treatment was sufficient to displace Hsp90 from LRRK2 (results not shown), but did not decrease the amount of LRRK2 recovered.
For LKKR2 autophosphorylation assays, reactions were initiated by the addition of 10 μM of non-radioactive ATP (Sigma) and 10 μCi of [γ - 33 P]ATP (PerkinElmer) and incubated at 30
• C for 30 min in an Thermomixer R (Eppendorf) at 1400 rev./min. The samples were run on SDS/PAGE (4-20 % Criterion TGX pre-cast gels), transferred on to PVDF membrane and exposed to phophoscreen, which was subsequently imaged on a Storm phosphorimager (Amersham Pharmacia Biosciences). The results of LRRK2 autophosphorylation were normalized to the amount of LRRK2 protein detected by Western blot against the FLAG peptide. Each experiment was repeated on 3-4 separate days with independent transfections, purifications and autoradiography measurements.
For estimation of LRRK2 substrate phosphorylation activity, the reaction was additionally supplemented with 200 μM lrrktide (Enzo Life Sciences). Equivalent amounts of radioactivity of the [γ -
33 P]ATP were added to each reaction, taking decay into consideration. At each time point, 20 μl aliquots were removed from the reaction, mixed with 10 μl of 0.5 M EDTA and applied to P-81 paper (Whatman). The P-81 paper was then dried, washed four times with 75 mM phosphoric acid (Sigma), immersed on to Bio-safe II (RPI) scintillation cocktail and activity was measured on an LS6500 scintillation counter (Beckman Coulter). The phosphorylation of lrrktide, estimated as c.p.m. incorporated in the first 30 min of the reaction, were normalized to the amount of protein detected by Western blot analysis and to the overall incorporation of radiolabel at 60 min, thereby correcting for small differences in the overall c.p.m.. Each experiment was repeated 3-4 times with independent transfections, protein purifications and time courses.
Metabolic labelling
HEK-293FT cells were transfected with 3×FLAG-LRRK2 constructs in 6-well plates. At 24 h after transfection, cells were washed twice in phosphate-free DMEM (Dulbecco's modified Eagle's medium; Invitrogen) and labelled in the same medium containing 40 μCi/well P-32 radionuclide disodium phosphate (PerkinElmer) for 4 h. After labelling, cells were collected in PBS, pH 7.4, and lysed in 1× lysis buffer (Cell Signaling), containing protease (Roche) and phosphatase (Thermo Scientific) inhibitors. After incubation on ice for 30 min, lysates were centrifuged at 12 000 g for 10 min at 4
• C. Supernatants were collected and precleared with 20 μl of EZview Red Protein G affinity gel for 30 min at 4
• C then incubated with 20 μl of EZview Red anti-FLAG M2 affinity gel (Sigma) for 1 h at 4
• C. Immunoprecipitated proteins were washed five times in buffer containing 25 mM Tris, pH 7.5, 400 mM NaCl and 1 % (v/v) Triton X-100 and subjected to SDS/PAGE. The results were from three independent transfections that were metabolically labelled and separated.
Co-immunoprecipitation
HEK-293FT cells were transfected with 3×FLAG-LRRK2. After 48 h, cells were lysed with buffer containing 20 mM Tris/HCl, pH 7.4, 137 mM NaCl, 3 mM KCl, 10 % (v/v) glycerol, 1 mM EDTA and 0.3 % Triton X-100 supplemented with protease inhibitor cocktail (Roche) and HALT phosphatase inhibitor cocktail (Thermo Scientific). Lysates were pre-cleared with EZview Red Protein G affinity gel for 1 h and immunoprecipitated with EZview Red anti-FLAG M2 affinity gel (both Sigma) for 2 h. The EZview Red anti-FLAG M2 affinity gel was then gently washed six times with buffer containing 20 mM Tris/HCl, pH 7.4, 137 mM NaCl, 3 mM KCl (all KD Medical) and 0.1 % Triton. LRRK2 was eluted with Gentle Ag/Ab elution buffer, pH 6.6 (Thermo Scientific) with 0.01 % Triton X-100 for 30 min. The eluate was desalted with the 7 kDa molecular mass cut-off Zeba Spin Desalting Columns (Thermo Scientific). Each co-immunoprecipitation was repeated in 3-4 independent experiments and quantification was performed by estimating the ratio of immunoprecipitated binding partner to the amount of LRRK2 construct pulled down on the beads.
Cell fractionation
HEK-293FT cells transiently transfected with different 3×FLAG-LRRK2 mutants or human lymphoblastoma cell line #00057 (Coriell) were homogenized in 1 ml of sedimentation medium (250 mM sucrose, 3 mM Tris/HCl, pH 7.3, 0.5 mM EGTA and protease inhibitors cocktail) by applying 20 gentle strokes of a Potter-Elvenhjem homogenizer. Mouse brains (FVB/N strain) were minced into 1-2 mm pieces prior to homogenization. The resulting homogenates were centrifuged at 1000 g for 10 min. The first pellet was discarded, 200 μl of supernatant was used as a total fraction and 800 μl was subsequently centrifuged at 10 000 g for 10 min. The second pellet was washed twice by gentle resuspention and centrifugation (10 000 g, 10 min) and used as a mitochondrial fraction. The second supernatant from cells was centrifuged in an optima MAX ultracentrifuge (Beckman Coulter) at 200 000 g (rotor MLA-130, 65 000 rev./min) for an additional 90 min, whereas the second supernatant from mouse brain tissues was centrifuged at 100 000 g (rotor MLA-130, 46 000 rev./min) for 60 min. The pellet after the third centrifugation was taken as the microsomal fraction and the supernatant as the cytosolic fraction. The volumes of all of the fractions were adjusted to 800 μl with sedimentation medium. All fractions were then lysed with lysis buffer, sonicated and cleared at 20 000 g for 10 min. All procedures were carried out at 4
• C. In each case, experiments are representative of triplicate purifications performed on different days. All of the mouse work followed the guidelines approved by the Institutional Animal Care and Use Committees of the National Institute of Child Health and Human Development.
Size-exclusion chromatography
HEK-293FT cells were harvested in PBS supplemented with protease inhibitors cocktail (Roche) and lysed using four freezethaw cycles in liquid nitrogen. In some experiments, we incubated the cells at 37
• C with 1 μM geldanamycin for 2 h before extraction. To inhibit the proteasome, we exposed cells to 25 μM MG132 alone or combined with 1 μM geldanamycin for 4 h at 37
• C. Insoluble material was removed from the lysates by centrifugation and lysates were then passed through 0.45 μm filters (Nanosep MF, Pall Life Sciences) prior to analysis. Sizeexclusion chromatography was performed using a BioAssist G4SW XL column (7.8 mm×30.0 cm, Tosoh Bioscience) with PBS as the mobile phase (0.8 ml/min, 4
• C). Samples (0.100 ml, 0.7 % of the total geometric column volume compared with a maximum recommended by the manufacturer of <2 %) were injected into the column and fractions (0.28 ml) were collected. Aliquots containing LRRK2 (elution volume 5.75-11.75 ml) were analysed by SDS/PAGE (4-20 % Tris-glycine gels) followed by Western blot analysis for FLAG-LRRK2. Thyroglobulin (660 kDa), ferritin (440 kDa) and IgM (∼ 1 mDa) were used as standards (Supplementary Figure S1 at http:// www.BiochemJ.org/bj/446/bj4460099add.htm). Distribution of LRRK2 in each fraction was estimated by measuring the integrated absorbance of the LRRK2 band corrected to the total amount of immunoreactivity in all fractions. Each construct or treatment was transfected on at least three separate days and results were compiled for all experiments.
DSF (differential scanning fluorimetry)
DSF was performed as described previously [17, 18] . Briefly, SYPRO Orange fluorescent dye (Invitrogen) was used to obtain thermal denaturation curves with excitation and emission wavelengths of 488 and 520 nm respectively and a thermal gradient from 25
• C to 99 • C in 1 • C increments on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Each 20 μl reaction contained 25 mM Hepes, pH 7.5, 150 mM NaCl, 0.02 % Triton X-100, 200 μg/ml 3×FLAG-peptide, 80 nM 3×FLAG-LRRK2 and 5× SYPRO Orange. The mid-point of thermal denaturation (T m ) was estimated as the temperature with the maximal first derivative of the normalized fluorescence. • C. Cells were then fixed with 4 % (w/v) paraformaldehyde in PBS, blocked with 5 % (v/v) FBS in PBS and stained with anti-FLAG antibody (Sigma) in blocking solution with the addition of 0.1 % Triton X-100 for 1 h. After several washes with PBS, anti-mouse antibody labelled with Alexa Fluor ® 488 (Invitrogen) and TO-PRO-3 nuclear stain (Invitrogen) were applied followed by additional washing steps. LRRK2 localization was imaged and counted by an operator blinded to construct/treatments using a Zeiss LSM510 META Confocal Imaging System with ×100/1.4 NA (numerical aperture) objective. At least triplicate experiments, with separate cultures and transfections, were used for each construct.
ImageStream analysis
HEK-293FT cells were transfected with 2×Myc-LRRK2 constructs and, 48 h later, trypsinized cells were fixed for 20 min in 4 % (w/v) PFA in PBS and then washed in PBS to remove the fixative. Cell suspensions were then incubated for 1 h at room temperature (22
• C) with mouse anti-Myc antibody (Roche) in 0.1 % Triton/5 % (w/v) FBS/PBS using 1 μg of antibody per 1×10 6 cells. Cells were washed with PBS and then incubated with the Alexa Fluor ® 647-conjugated goat anti-(mouse IgG) secondary antibody (Invitrogen) for 40 min at room temperature. After washing, cells were counterstained using 10 μg/ml DAPI (4 ,6-diamidino-2-phenylindole) (Invitrogen) for 5 min at room temperature then washed in PBS. The cells were assayed using the Amnis ImageStream X flow cytometer and imaged using a ×40/0.75 NA objective. A far-red diode laser (658 nm) and a violet diode laser (405 nm) were used to excite Alexa Fluor ® 647 and DAPI respectively, and a standard filter array and a high-resolution camera was used to image the cells labelled with each dye. The data were processed using IDEAS image analysis software (Amnis). Approximately 500 Myc (LRRK2)-positive cells per construct were analysed for the presence/absence of inclusions and the percentage of inclusion-positive cells was calculated as the number of cells with inclusions divided by the total number of LRRK2-positive cells multiplied by 100.
Neurite outgrowth measurements
M17 human neuroblastoma cells were seeded on poly-D-lysinecoated (0.05 mg/ml) Lab Tech II two-well chambers (Nalge Nunc) at 10 5 cells/well and differentiated for total of 9 days with 10 μM retinoic acid (Sigma). After 7 days of differentiation, the cells were transfected with 3×FLAG-LRRK2 constructs using Effectene ® (Qiagen). After 48 h, the cells were fixed with 4 % (w/v) paraformaldehyde in PBS and stained using mouse anti-FLAG antibody (1:400 dilution, Sigma Clone M2) and chicken anti-β-III-tubulin antibody (1:400 dilution, Novus Biologicals) followed by anti-mouse-Alexa Fluor ® 488 and antichicken-Alexa Fluor ® 647 (both at 1:500 dilution, Invitrogen). LRRK2-positive cells were imaged using a Zeiss LSM510 META Confocal Imaging System with a ×63/1.4 NA objective and neurite length was determined by tracing the entire length of the longest process from the centre of the cell using ImageJ (http://rsbweb.nih.gov/ij/). Each experiment was repeated at least three times with independent batches of cells and transfections.
Statistical analysis
For comparisons of multiple LRRK2 constructs, one-way ANOVA was used with Tukey's honest significance post-hoc test for individual comparisons. In experiments where different LRRK2 constructs were used in the absence and presence of geldanamycin, we used two-way ANOVA with mutant and treatment as factors, with Bonferroni post-hoc test to compare the effects of geldanamycin against DMSO treatment for each construct.
RESULTS
The G2385R LRRK2 mutant has decreased kinase activity
To test the effect of the G2385R variant on kinase activity, we designed a set of mutants with G2385R substitution and C-terminally truncated forms of LRRK2 either on a Figures 1D and 1E ) assays.
To further delineate the regions of the C-teminus required to influence kinase activity, we introduced stop codons just before (1-2140 or LRRK2 WD40) or just after (1-2498 or LRRK2 C) the predicted WD40 domain of the protein. Both deletions completely abolished the autophosphorylation activity of the WT or G2019S protein ( Figures 1B and 1C) . Similar results were obtained for 2×Myc-LRRK2 constructs (results not shown). The truncated forms of LRRK2 also showed no lrrktide phosphorylation activity, similar to the kinase-dead version (K1906M) of the protein (Figures 1D and 1E) .
These results show that the extreme C-terminus is essential for LRRK2 kinase activity and this effect is sufficient to overcome the activating effect of G2019S. Additionally, the G2385R mutation decreases kinase activity by approximately 40 % and does not change the ratio in decrease of phosphorylation activity between WT and G2019S LRRK2 backgrounds. In turn, this indicates that the G2385R variant has a partial effect on LRRK2 kinase activity and supports the concept that the WD40 domain and C-terminus influence the activity of the kinase domain of LRRK2.
LRRK2 predominantly localizes to microsomes
It has been suggested that the subcellular localization of LRRK2 could affect its biochemical properties, with membraneassociated protein-forming kinase-active dimers [19] . We considered whether the WD40 domain and the extreme Cterminus could influence the intracellular distribution of the protein and therefore explain the effects on activity. To test this hypothesis, we performed fractionation of HEK-293FT cells transiently transfected with WT and G2385R LRRK2 as well as WD40-and extreme-C-terminus-deleted mutants. All LRRK2 isoforms were predominantly associated with the microsomalenriched fraction of HEK-293FT cells. A smaller portion of 3×FLAG-LRRK2 was found in the cytosol, with only small amounts in the mitochondria-enriched fraction (Figure 2A ). Because it has been suggested that LRRK2 is found in the mitochondria, we also performed immunocytochemistry for LRRK2 with Mitotracker Orange staining. Again, the amount of LRRK2 costaining with mitochondria was modest (Supplementary Figure S2 at http://www.BiochemJ.org/bj/446/ bj4460099add.htm). Endogenous LRRK2 had a similar pattern of subcellular fractionation in human lymphoblastoid cells ( Figure 2B ) and mouse brain tissue ( Figure 2C) , although the quality of fractionations for these types of cells/tissue was not as good as for HEK-293FT cells, seen as contamination of cytosolic and mitochondrial fractions with microsomal markers [γ -adaptin or PDI (protein disulfide-isomerase)].
These results suggested that LRRK2 is found predominantly in microsomal fractions and allowed us to test whether the G2385R mutation altered this. Deletion of the WD40 domain together with the extreme C-terminus slightly shifted the 3×FLAG-LRRK2 fractionation pattern to the cytosol, but the majority remained microsomal. G2385R substitution or deletion of the extreme C-terminus alone did not change the fractionation profile of 3×FLAG-LRRK2 (Figure 2A) . Similar results were
Figure 2 Distribution of LRRK2 in cellular compartments
(A) Full-length WT and G2385R 3×FLAG-LRRK2 as well as C-terminally truncated forms ( C and WD40, as described in Figure 1A ) of the protein are predominantly associated with the microsomal-enriched fraction when transiently expressed in HEK-293FT cells. (B and C) Endogenous LRRK2 was mostly found in the microsomal-enriched fraction of lymphoblastoid cells or whole-brain homogenates of 2-month-old mice (FVB/N) using MJF2 antibody. The following subcellular markers were used for fraction identification: PDI for endoplasmic reticulum (ER) or γ -adaptin for trans-Golgi (both second panels), MEK1/2 (mitogen-activated protein kinase/extracellular-signal-regulated kinase kinase) for cytosol (third panels) and Tom 20 for mitochondria (bottom panels). Each fractionation is representative of triplicate experiments performed at different times. Tg, transgenic.
obtained with 2×Myc-LRRK2 mutants (results not shown). Therefore the absence of kinase activity in C-terminally truncated LRRK2 mutants and reduced autophosphorylation and lrrktide phosphorylation found in G2385R variant is not due to a change of subcellular distribution.
The G2385R mutation changes the behaviour of LRRK2 under native separation techniques
For many kinases, proper folding is crucial for normal phosphorylation activity and structural stability [20, 21] . To examine the effects of mutations on the behaviour of LRRK2 under native conditions, we used size-exclusion chromatography and found that WT, G2019S and K1906M 3×FLAG-LRRK2 eluted over a broad range of molecular masses from ∼ 400-1000 kDa, but before the void volume of the column (Supplementary Figure S1) . Within this range, there was a higher signal for LRRK2 immunoreactivity centred at 10 ml and a shoulder of the separation at ∼ 8.5 ml (Figures 3A and 3B) , which are estimated to be between 440 and 660 kDa and between 660 and 800 kDa respectively. A small amount of LRRK2 eluted at very high molecular masses (>1 mDa), but before the void volume of the column. Surprisingly, C-terminally truncated forms of LRRK2 ( WD40 and C) were eluted from the column at lower volumes, with the highest immunoreactivity found at ∼ 8.5 ml, despite the fact that they have lower molecular masses compared with the intact protein. Furthermore, proteins with the G2385R substitution tended to elute more in the ∼ 8.5 ml fraction compared with WT protein (Figures 3A and 3B ). To capture this behaviour, we considered that the 440-600 kDa and 660-800 kDa regions of the separation as potentially distinct protein complexes, which we labelled α and β for clarity ( Figure 3A) . Under these separation conditions, these two regions are not (A) Size-exclusion chromatography was used to demonstrate that WT, G2019S and K1906M 3×FLAG-LRRK2 have elution volumes between 440 and 660 kDa (complex α), a second region of ∼ 600-800 kDa (complex β) and a minor amount eluting at a higher molecular mass. C-terminally truncated LRRK2 mutants elute at relatively higher apparent molecular mass compared with WT protein and the G2385R variants elute broadly. Markers indicate elution volumes of the standards ferritin (440 kDa), thyroglobulin (660 kDa) and IgM (∼ 1 mDa). (B) Quantification of the amounts of LRRK2 in each fraction compared with total immunoreactivity for all fractions for constructs as indicated (n = 3, means + − S.E.M.). (C) Summary of the ratio of complex α to complex β. The percentage of total LRRK2 was calculated for each fraction collected, and the sums of the three fractions representing complexes α and β were used to calculate the ratios shown. Statistical significance relative to WT was assessed by one-way ANOVA with Tukey's honest significance test (*P < 0.05; ***P < 0.001; ns, not significant; n = 3). rel. un., relative units.
completely distinct and we defined complex α representing elution volume 9.67-10.23 ml, whereas complex β represents 8.27-8.83 ml. Calculating the ratio of the amount of protein in the lower molecular mass to the higher molecular mass complexes, we found a striking effect of the deletion mutations and an intermediate effect of the G2385R mutation either on a WT or G2019S background ( Figure 3C ). These results show that the apparent molecular mass of WT LRRK2 is approximately 600 kDa, as previously reported [12, 22, 23] , whereas the two truncated proteins exist as apparently higher molecular mass species, also consistent with previous results [12] . Surprisingly, the G2385R mutant exhibits an intermediate behaviour between these two extremes.
The shift towards apparently higher molecular masses caused by the deletion of the C-terminus, despite the smaller size of the protein, or to a lesser extent the G2385R substitution, could be explained by conformational shifts that increase its hydrodynamic volume. To test whether the G2385R mutation destabilized LRRK2, we used DSF [17] . DSF did not reveal any difference in thermal stability between WT and G2385R LRRK2 (Supplementary Figure S3 at http://www.BiochemJ. org/bj/446/bj4460099add.htm). These results indicate that the G2385R substitution does not grossly perturb the secondary structure of LRRK2 to the level at which we can detect with DSF. We therefore next considered whether the apparent increase in molecular mass of some of these variants might be due to enhanced associations with protein-binding partners.
The G2385R mutation affects protein-protein interactions of LRRK2
LRRK2 has a number of known protein-protein interaction partners and, as well as being a kinase, LRRK2 is also a phosphoprotein. 14-3-3 proteins bind LRRK2 at Ser 910 and Ser 935 in a manner that depends on an unknown kinase that phosphorylates these sites [16, 24, 25] . This effect is also sensitive to overall conformation of LRRK2, as mutations in the ROC and COR domains that do not alter kinase activity can also disrupt phosphorylation and recruitment of 14-3-3. Furthermore, LRRK2 is also known to bind the Hsp90 Cdc37 (cell division cycle 37 homologue), probably via the kinase domain [26] .
In order to estimate binding, we performed immunoprecipitation experiments against endogenous Hsp90, Cdc37 and Statistical significance relative to WT was assessed by one-way ANOVA with Tukey's honest significance test (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant). All experiments were replicated at least three times. Results are presented as means + − S.E.M. Arb. Un., arbitrary units. Figure 4A ). Strikingly, both deletion of the extreme C-terminus and G2385R mutation caused an increase in Hsp90 binding to LRRK2, which correlated with higher binding of Cdc37 (Figures 4A-4C ). Interestingly, that interaction with Hsp90 was independent of kinase activity of LRRK2, as a kinase-dead (K1906M) mutant bound Hsp90 similarly to WT protein. Although 14-3-3 proteins were bound by WT and kinase-dead (K1906M) 3×FLAG-LRRK2 in simlar amounts, the 14-3-3-binding ability of the G2385R mutant was significantly decreased compared with WT protein and the extreme C-terminus deficient mutant did not bind any detectable amount of 14-3-3 proteins (Figures 4A and 4D Collectively, these results suggest that one of the effects of mutations at the C-terminus of LRRK2 is to change binding to several protein-interaction partners. Given this, we next asked whether binding of one of these was sufficient to explain the behaviour of LRRK2 under native conditions noted in our earlier experiments.
14-3-3 proteins (
Hsp90 contributes to the behaviour of G2385R LRRK2 under native conditions
Taking into consideration the stronger association of Hsp90 with LRRK2 mutants that eluted at higher apparent molecular masses compared with the WT protein, we hypothesized that the binding of Hsp90 itself could be important to mobility under native conditions. In order to test this, we treated 3×FLAG-LRRK2-transfected HEK-293FT cells with the Hsp90 inhibitor geldanamycin (1 μM) for 2 h before lysing the cells and separating proteins using size-exclusion chromatography. Inhibition of Hsp90 binding changed the elution profiles of G2385R and the extreme C-terminally truncated LRRK2 (Figures 5A and 5B) . Pretreatment with 1 μM geldanamycin for 2 h selectively diminished the relative amount of the G2385R protein that eluted in the slightly higher apparent molecular mass fractions, labelled as complex β, and the elution profile of the C-terminally truncated protein was shifted to higher molecular masses ( Figures 5A and 5B) . A smaller effect was seen with WT LRRK2. These results suggest that disruption of a single binding partner, Hsp90, is sufficient to change the native elution profile of LRRK2, suggesting that the two regions of the native separation represent distinct protein complexes.
Hsp90 can help fold and stabilize LRRK2, and prevent degradation by the proteasome [27] . Under native conditions, we saw accumulation of a small amount of very high molecular mass species that eluted before the void volume of the column for WT, G2385R and C-terminally truncated LRRK2, particularly for the truncated construct ( Figures 5A and 5B ). These fractions were enhanced when we treated cells with the proteasome inhibitor MG132 (25 μM) alone for 4 h ( Figures 5C and 5D) . Importantly, the accumulation of the high molecular mass species of the G2385R and C-terminally truncated LRRK2 mutants was facilitated by additional inhibition of Hsp90 binding with geldanamycin (1 μM), whereas WT protein was less affected.
As the behaviour of the high molecular mass native species was distinct, and responded to MG132, we infer that these >1 mDa regions represent LRRK2 associated with the proteasome, but not yet degraded. We therefore labelled these as complex γ , assuming that they represent LRRK2 bound to different partners than the other two regions of the separation. We used these three complexes to summarize the effects of geldanamycin and MG132 treatment on the behaviour of LRRK2 under native conditions. In the geldanamycin experiment, we see that there is a decrease in complex β, and that this reaches statistical significance for G2385R and the C-terminal deletion construct ( Figure 5E ). Conversely, incubation with MG132 alone increases the amount of the high molecular mass species labelled as complex γ significantly for all constructs ( Figure 5F ). This effect is increased further for G2385R and the C-terminally deleted LRRK2 in the presence of geldanamycin. Collectively, these results suggest that Hsp90 is essential for maintaining the stability of LRRK2 and inhibition of this activity promotes proteasomal degradation of LRRK2 [27] , although it should be noted that the timing of exposure in the current experiments was deliberately short to minimize the loss of LRRK2 owing to proteasome turnover. Furthermore, these results suggest that the chaperone activity of Hsp90 is more important for the G2385R mutant compared with the WT LRRK2.
Hsp90 does not control the kinase activity of LRRK2
Given the increased association of Hsp90 to G2385R and, to a greater extent, C-terminally truncated LRRK2 compared with other variants, we next asked whether this enhanced binding was responsible for the lower observed kinase activity. To test this, we exposed cells to 1 μM geldanamycin for 2 h then extracted LRRK2 and measured kinase activity using autophosphorylation ( Figures 6A and 6B) or lrrktide ( Figures 6C and 6D) assays. In both sets of assays, we replicated the results in Figure 1 that G2019S had higher (∼ 250 %), and G2385R and C-terminally truncated had lower (∼ 60 %) of WT protein. However, we found that geldanamycin did not alter the activity of any of the variants. Using two-way ANOVA, the difference between mutations was highly significant (P < 0.0001), whereas the effect of geldanamycin was not and there was no significant interaction term. These results show that Hsp90 is not important for the kinase activity of LRRK2 and more likely influences protein folding and/or turnover by the proteasome.
The G2385R substitution prevents formation of skein-like structures in HEK-293FT cells
The results discussed above suggest that C-terminal deletions and G2385R mutation decrease kinase activity. However, it remains possible that these results are true only in vitro and might not be reflective of the effects of mutations within living cells. Recognizing that there is no well-established direct measure of LRRK2 kinase activity in vivo, we used several phenotypes that have been proposed to depend on the kinase activity of LRRK2.
It has been shown previously that dephosphorylation of Ser 910 and Ser 935 , associated with loss of 14-3-3 binding, causes the formation of skein-like inclusions in HEK-293FT cells [24] . These effects can be triggered using the application of the LRRK2-selective inhibitor LRRK2-IN-1 [28] . Using this approach, we confirmed that LRRK2-IN-1 caused redistribution of kinase-active WT and G2019S LRRK2 to skein-like structures, but did not change the localization of the kinase-dead K1906M LRRK2 mutant. In contrast, neither C-terminally truncated LRRK2 mutants nor proteins with the G2385R substitution revealed the formation of skein-like inclusions before or after the treatment with LRRK2-IN-1 ( Figure 7A ). Similar results were seen in SH-SY5Y cells (Supplementary Figure S4 at http://www.BiochemJ.org/bj/446/bj4460099add.htm). These results suggest that the C-terminal deletions and the G2385R mutations are insensitive to inhibition by LRRK2-IN1 in a cellular context and that the loss of 14-3-3 binding by itself is not sufficient to cause inclusion body formation.
We supplemented these assays with an automated unbiased ImageStream analysis. The percentage of HEK-293FT cells with inclusions correlated with the kinase activity of LRRK2 mutants, in that the G2019S mutant demonstrated an increased proportion of cells with inclusion bodies, whereas D1994A kinase-dead LRRK2 revealed a decrease in formation of these structures (Supplementary Figure S5 at http://www.BiochemJ. org/bj/446/bj4460099add.htm). G2385R and G2019S/G2385R double LRRK2 mutant did not show a significant difference in the percentage of cells with inclusions compared with the WT protein.
Additionally, deletion of the C-terminus completely abolished inclusion body formation, again consistent with the hypothesis that these mutations are kinase dead in a cellular context. Finally, we measured neurite length in the M17 neuroblastoma cell line, which has also been shown to be dependent on LRRK2 kinase activity [29] . Replicating previous work, we found that the activating the G2019S mutation decreased the average length of neurites and, at these levels of overexpression, we did not see an effect of WT LRRK2 compared with a control protein, GFP (green fluorescent protein; Figures 7B and 7C) . Importantly, deletions of the C-terminus or inclusion of the G2385R mutation placed on a G2019S background prevented the neurite shortening effect. Overall, these results show that, in independent assays of LRRK2 in intact cells, the C-terminus is required for kinase activity and that the G2385R mutant behaves as a kinase-dead protein in a cellular context. . Statistical significance relative to DMSO treatment alone was assessed using one-way ANOVA with Tukey's honest significance test (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant).
DISCUSSION
In the present study we investigated the effects of the G2385R mutation on the function of LRRK2. As G2385R is a risk factor for PD, we predicted that it might share some properties with mutations that are inherited in a Mendelian manner, although perhaps with a quantitatively smaller effect. Surprisingly, we found that, in many assays, G2385R behaves in the opposite way to pathogenic mutations and can in some assays overcome the effects of the G2019S variant that has attracted much attention because of its ability to cause kinase activation. In our studies, the G2385R mutant of LRRK2 has a decreased kinase activity, reduced phosphorylation of the Ser 910 /Ser 935 sites and a concomitant diminished ability to bind 14-3-3 proteins. In contrast, there was higher binding to Hsp90 which correlates with an accumulation of slightly higher molecular mass forms under native separation conditions. The cellular effects of the protein with G2385R substitution were also different from those of WT LRRK2 and, again, were sufficient to overcome the effects of the G2019S mutation when the two variants were placed on the same molecule ( Table 1) .
Binding of Hsp90 to LRRK2 has been reported previously by several independent groups [27, [30] [31] [32] . The results from the present study confirms this and suggests that Hsp90 plays an important role in formation of the proportion of LRRK2 that separates at apparently higher molecular mass using native techniques such as size-exclusion chromatography. Mutations such as G2385R and, more dramatically, deletions of the C-terminus that bind Hsp90 more tightly than WT LRRK2, cause a shift towards these higher apparent molecular mass regions of the separation. As brief treatment of cells with the Hsp90 inhibitor geldanamycin decreases the amount of LRRK2 separating between ∼ 660 and 800 kDa, we infer that this species represents LRRK2 bound to chaperone complexes. Owing to the accumulation of LRRK2 at very high molecular mass fractions (>1 mDa, but below the void volume of the column used in the present study) after treatment with the proteasome inhibitor MG132, we further infer that these fractions represent LRRK2 that is associated with, and would normally be degraded by, the proteasome. The proteasome is at least one pathway by which LRRK2 is degraded [27] and our proposal is that Hsp90 binding occurs to maintain properly folded LRRK2 protein and prevent such degradation.
The behaviour of LRRK2 under size-exclusion chromatography in the present study is largely consistent with previous studies using native separation techniques that identify a prominent region of immunoreactivity at ∼ 500-600 kDa. Given the limitations of precision of molecular mass estimates of sizeexclusion chromatography, this has been previously interpreted to represent dimeric LRRK2 [22, 23] , but this interpretation has been challenged using alternative techniques that suggest it may represent the LRRK2 monomer [33] . In the absence of a source of LRRK2 purified to homogeneity, this interpretation will probably remain uncertain, but the overall behaviour of LRRK2 is consistent between laboratories, as is the presence of a range of species at higher apparent molecular masses discussed above. One discrepancy is that, in our previous work [22] , a triple kinase-dead mutant of LRRK2 (K1906A/D1994A/D2017A) eluted above 600 kDa and into the void volume of the column used, whereas, in the present study the single kinase mutant (K1906M) eluted predominately between 660 and 440 kDa. Although we cannot directly compare these experiments performed under different conditions, we have since found the triple kinase-dead to be partly unstable in cells, as are some mutations that cause LRRK2 to lack the ability of binding to GTP/GDP, such as the present study, does not demonstrate enhanced Hsp90 binding so is likely to be more properly folded and therefore may be a more useful kinase-dead construct than less conservative mutations. The lack of effect of K1906M on the behaviour of LRRK2 in terms of formation of different protein complexes is important to the interpretation of our current results. As the C-terminal deletion constructs are kinase inactive, and G2385R is less kinase active, the behaviour of the protein might be due either to diminished kinase activity or related more directly to the role of the C-terminus in LRRK2 behaviour. WT, K1906M and G2019S LRRK2 all demonstrated similar in vivo phosphorylation patterns and were phosphorylated specifically at Ser 910 and Ser 935 , consistent with previously published results [16, 24] , which is likely to be because LRRK2 is predominantly phosphorylated in vivo by other kinase(s). Consequently, kinase-dead LRRK2 (K1906M) maintained its ability to bind 14-3-3 proteins and has a similar elution profile to the WT protein on size-exclusion chromatography considering the specific behaviour of the protein around 500-800 kDa. The strong effect of C-terminal deletions and the moderate effect of G2385R on phosphorylation of LRRK2 leads us to propose that the WD40 domain and C-terminus are important in either recruiting other kinases to LRRK2 and/or influence the availability of Ser 910 /Ser 935 to other kinases or phosphatases.
Although the three-dimensional structure of LRRK2 is not currently solved, several pieces of indirect evidence suggest that deletion of the extreme C-terminus of LRRK2 leads to a change in the protein conformation of LRRK2. As deletions or point mutations in the WD40 domain of LRRK2 lead to abolished or decreased kinase activity, this implies that the overall fold of the protein is important for maintaining the kinase domain in its active state. Given that these regions are separated by several hundred amino acids in the primary sequence, it seems unreasonable to infer a very local event in the kinase domain itself, although this cannot be excluded without a structure that includes both regions. We have shown previously that the WD40 domain and C-terminus binds to the ROC domain of LRRK2 and speculate that the WD40-C-terminal region plays a role in the tethering of the kinase domain, maintaining the relative orientation of the two lobes of the kinase domain within the multidomain protein [22] . Furthermore, the discovery that the G2385R variant or C-terminal deletions can overcome the hyperactivating effect of G2019S when placed on the same molecule might imply that this is probably an intra-rather than an inter-molecular event, i.e. self-interaction within a monomer rather than between monomers within a dimer. Again, both of these hypotheses are speculative without detailed structures against which to test them.
What is clear is that the binding of Hsp90 is not responsible for the decrease in kinase activity of C-terminal mutations in LRRK2. Incorporating all of the available data into one model, it is therefore likely that the effects of mutations in the C-terminal region that influence kinase activity are also recognized independently by chaperones as being imperfectly folded. If the C-terminus does indeed play a role in maintaining the overall multidomain fold of LRRK2, then loss of the C-terminus may lead to unfolding of the molecule, exposing new regions for Hsp90 interaction.
An outstanding question is why G2385R has a relatively strong effect in these assays. It is possible that the neutral and flexible glycine residue, which is predicted to be on the outer surface of the WD40 domain [34] , also plays a role in overall folding of the molecule. Substitution of Gly 2385 with a positively charged arginine residue might have a locally destabilizing effect. Interestingly, it has been already shown in transferrinand collagen-related disorders that glycine to arginine residue substitutions can lead to the simultaneous formation and existence of several forms of the same protein [35, 36] . Whether this occurs for mutant, or WT, LRRK2 is not clear at this time.
Several groups have proposed that selective inhibition of LRRK2 kinase activity is a promising therapeutic strategy for the treatment of PD caused by a single mutation in the LRRK2 gene [7, 28, 37] . One surprise from the present study, and against our initial hypothesis, was that G2385R, a very well-established genetic risk factor for sporadic PD, robustly decreased kinase activity. This contrasts with the increase in kinase activity for G2019S and with the reports that kinase activity is important for neurotoxicity in model systems. The implication of this result for pathogenesis is uncertain. One possibility is that the kinase activity of LRRK2 can be tolerated over only a narrow range, i.e. that both loss or gain of function variants are pathogenic, which would then imply that LRRK2 inhibitors would probably have a very narrow therapeutic index. However, it is also possible that the G2385R substitution changes the scaffolding properties of the protein and that this can lead to pathogenic effects. If this is true, then blocking kinase activity would not be the only way in which to interfere with LRRK2 dysfunction, raising important additional therapeutic avenues for PD [38] .
In summary, the present study shows that the G2385R LRRK2 mutant is a partial loss-of-function mutation. G2385R has lower kinase activity of LRRK2 and altered binding to several currently validated protein interactions. Future studies will be important to understand how G2385R act as a risk factor for PD and whether kinase activity is important for the actions of this mutation. Figure S1 Size-exclusion chromatography calibration (A) Elution profiles of purified protein standards run on a TSKgel BioAssist G4SWXL column. Thyroglobulin, ferritin, aldolase, conalbumin and ovalbumin were obtained from a commercially available calibration kit (High Molecular Weight Calibration Kit; GE Lifesciences), whereas purified bovine IgM was obtained from Sigma (Product I8135, estimated molecular mass of 1 mDa). Acetone (58 Da) was run on the column to demonstrate the total column volume. (B) A typical elution profile of lysate from HEK-293FT cells transfected with LRRK2 and run on a TSKgel BioAssist G4SWXL column. We found that the column resolved Blue Dextran, which is typically used to determine the void volume (V 0 ) of size-exclusion columns. Therefore, we determined the V 0 of this column experimentally by observing the volume where substances that absorbed 280 nm light began to elute from the column.
Figure S2 LRRK2 does not colocalize with mitochondrial marker
(A) Confocal images depicting the localization of different mutants of 3×FLAG-LRRK2 (green) in HEK-293FT cells. Mitochondria were stained with Mitotracker Orange (red). Colocalization between 3×FLAG-LRRK2 and mitochondria along the region of the cells depicted with arrows was analysed using intensity profile algorithm on a Zeiss LSM510 META confocal microscope. Representative scans for 3×FLAG-LRRK2 WT (B) and G2385R (C) are shown. rel.un., relative units. SH-SY5Y cells were transfected with 3×FLAG-LRRK2 constructs and treated for 2 h with DMSO (upper panels) or LRRK2-IN1 (lower panels). Cells were fixed in 4 % (w/v) paraformaldehyde and stained for 3×FLAG (green) and nuclei (blue). A magnified example of the skein-like inclusions is shown below the panel.
